|Bid||1.03 x 1400|
|Ask||9.50 x 1100|
|Day's Range||7.71 - 9.03|
|52 Week Range||6.70 - 20.07|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Cambridge, Massachusetts-based company said it had a loss of 34 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 41 cents. For the year, the company reported a loss of $17.6 million, or $3.04 per share. LogicBio Therapeutics shares ...
The four-year-old biotech is planning to seek FDA approval for its first clinical trial by the end of the year, executives told the Business Journal this week.
Earnings and U.S. midterm polls continued to positively influence biotech stocks, with the sector notching gains for the second straight week. These are some of the upcoming week's catalysts that could ...
This technology is designed to precisely integrate corrective genes into a patient’s genome to provide a therapeutic effect, according to the company's S-1 filing. The company’s lead product candidate LB-001 is designed to treat methylmalonic acidemia, when the body cannot break down specific proteins and fats. The next steps in clinical research should be initiated by the end of 2019, according to LogicBio.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . PhaseBio Pharmaceuticals Inc (PHAS) will issue 5 million shares between $12 and $14 Thursday on the Nasdaq. Based in Pennsylvania, ...